Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
作者信息
Yamasoba Daichi, Kosugi Yusuke, Kimura Izumi, Fujita Shigeru, Uriu Keiya, Ito Jumpei, Sato Kei
机构信息
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan; School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
出版信息
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
Abstract
摘要
相似文献
1
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体对治疗性单克隆抗体的中和敏感性
Lancet Infect Dis. 2022 Jul;22(7):942-943. doi: 10.1016/S1473-3099(22)00365-6. Epub 2022 Jun 9.
2
Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19.奥密克戎时代 COVID-19 中和单克隆抗体治疗的现状与发展策略。
Viruses. 2023 May 31;15(6):1297. doi: 10.3390/v15061297.
3
Neutralizing antibodies for SARS-CoV-2 infection.针对 SARS-CoV-2 感染的中和抗体。
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):16-19. doi: 10.37201/req/s03.04.2022. Epub 2022 Oct 24.
4
A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.一种能够破坏 Spike 的人源抗体，可有效中和包含奥密克戎在内的 SARS-CoV-2 变异株，并具有治疗效果。
PLoS Pathog. 2023 Jan 27;19(1):e1011085. doi: 10.1371/journal.ppat.1011085. eCollection 2023 Jan.
5
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
6
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.MW06 是一种人源单克隆抗体，对 SARS-CoV-2 和 SARS-CoV 均具有交叉中和活性。
MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.
7
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.针对严重急性呼吸综合征冠状病毒 2 株 delta 和 omicron 变异株的单克隆抗体的临床疗效和体外中和能力。
J Med Virol. 2022 Oct;94(10):5038-5043. doi: 10.1002/jmv.27916. Epub 2022 Jun 11.
8
Monoclonal Antibodies for Prevention and Treatment of COVID-19.用于预防和治疗新型冠状病毒肺炎的单克隆抗体。
JAMA. 2020 Jul 14;324(2):131-132. doi: 10.1001/jama.2020.10245.
9
Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage.新型冠状病毒感染期间中和抗体的相关性及其治疗用途。
Mol Biol Rep. 2022 Oct;49(10):10137-10140. doi: 10.1007/s11033-022-07493-z. Epub 2022 May 21.
10
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.用于治疗和预防 SARS-CoV-2 感染的中和单克隆抗体。
New Microbiol. 2021 Jul;44(3):135-144.
引用本文的文献
1
Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy.基于类器官的中和试验揭示了SARS-CoV-2抗体的独特特征，并概括了实际疗效。
Proc Natl Acad Sci U S A. 2025 Sep 2;122(35):e2509616122. doi: 10.1073/pnas.2509616122. Epub 2025 Aug 28.
2
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 disease.一项随机试验中，比较针对门诊中重症 COVID-19 疾病高风险人群的早期治疗方法的 CT 变化。
Sci Rep. 2025 Aug 18;15(1):30244. doi: 10.1038/s41598-025-15641-1.
3
Therapeutic Antibodies for Infectious Diseases: Recent Past, Present, and Future.用于传染病的治疗性抗体：过去、现在与未来
Biochemistry. 2025 Aug 19;64(16):3487-3494. doi: 10.1021/acs.biochem.5c00192. Epub 2025 Aug 7.
4
Cross-neutralization ability of anti-MERS-CoV monoclonal antibodies against a variety of merbecoviruses.抗中东呼吸综合征冠状病毒单克隆抗体对多种默贝病毒的交叉中和能力。
Front Microbiol. 2025 Jul 16;16:1593095. doi: 10.3389/fmicb.2025.1593095. eCollection 2025.
5
Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants.干粉形式的工程化血管紧张素转换酶2（ACE2）诱饵用于吸入：一种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的新型疗法。
Mol Ther Methods Clin Dev. 2025 Mar 31;33(2):101459. doi: 10.1016/j.omtm.2025.101459. eCollection 2025 Jun 12.
6
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective.四类免疫功能低下人群中发生重症新型冠状病毒肺炎的风险：法国专家观点
Infect Dis Ther. 2025 Apr;14(4):671-733. doi: 10.1007/s40121-025-01124-3. Epub 2025 Mar 18.
7
Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异突变对单克隆抗体和抗病毒药物敏感性的影响：一项非系统性综述，2022年4月至2024年10月
Euro Surveill. 2025 Mar;30(10). doi: 10.2807/1560-7917.ES.2025.30.10.2400252.
8
production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection.工程化血管紧张素转换酶2诱饵的产生可保护肺部免受严重急性呼吸综合征冠状病毒2感染。
Mol Ther Nucleic Acids. 2025 Jan 29;36(1):102467. doi: 10.1016/j.omtn.2025.102467. eCollection 2025 Mar 11.
9
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.严重急性呼吸综合征冠状病毒2的进化：对诊断、治疗、疫苗有效性及研发的影响
Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.
10
Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.一种ACE2-Fc融合蛋白对SARS-CoV-2及其变体的抗病毒活性。
PLoS One. 2025 Jan 3;20(1):e0312402. doi: 10.1371/journal.pone.0312402. eCollection 2025.
本文引用的文献
1
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.S309 和 AZD7442 单克隆抗体治疗对 SARS-CoV-2 奥密克戎谱系株感染的抵抗力。
Nat Commun. 2022 Jul 2;13(1):3824. doi: 10.1038/s41467-022-31615-7.
2
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.BA.2.12.1、BA.4 和 BA.5 逃避奥密克戎感染诱导的抗体。
Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17.
3
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.接受单克隆抗体治疗的患者对 SARS-CoV-2 奥密克戎亚谱系 BA.1 和 BA.2 的血清中和作用。
Nat Med. 2022 Jun;28(6):1297-1302. doi: 10.1038/s41591-022-01792-5. Epub 2022 Mar 23.
4
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
5
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.SARS-CoV-2 Lambda 变体表现出增强的感染力和免疫抗性。
Cell Rep. 2022 Jan 11;38(2):110218. doi: 10.1016/j.celrep.2021.110218. Epub 2021 Dec 18.
6
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）B.1.617的L452R和E484Q突变在抗体逃逸方面不存在协同作用。
J Infect Dis. 2021 Sep 17;224(6):989-994. doi: 10.1093/infdis/jiab368.
Zotero 插件